Objective: To explore the efficacy of different administration methods and doses of glucocorticoid in the treatment of children with acute infectious laryngitis. Methods: A total of 240 children with acute infectious laryngitis with grade Ⅰ to Ⅲ laryngeal obstruction admitted into our hospital from Jun. 2016 to Jun. 2019 were extracted to be randomly divided into the observation group and the control group

with 120 cases in each group. Both groups were given conventional anti-infection and symptomatic support treatment. In the observation group

children with grade Ⅰ and Ⅱ laryngeal obstruction were given budesonide nebulized inhalation

while children with grade Ⅲ laryngeal obstruction received high-dose dexamethasone intravenously based on budesonide nebulized inhalation. In the control group

children with grade Ⅰ and Ⅱ laryngeal obstruction were given regular-dose dexamethasone intravenously

and children with grade Ⅲ laryngeal obstruction received regular-dose dexamethasone intravenously based on budesonide nebulized inhalation. The relief time of clinical symptoms

adverse drug reactions and nosocomial infection of two groups were observed. Results: After treatment

the relief time of dyspnea

hoarseness

inspiratory stridor and barking cough in the observation group was shorter than that in the control group (P<0.05). The total effective rate of the observation group with grade Ⅰ

Ⅱ and Ⅲ laryngeal obstruction was higher than that of the control group (P<0.05). There was no significant difference in the incidence of adverse drug reactions and nosocomial infection between two groups (P>0.05). Conclusion: Budesonide nebulized inhalation for children with Ⅰ degree and Ⅱ degree laryngeal obstruction

high-dose dexamethasone on the basis of budesonide nebulized inhalation for children with Ⅲ degree laryngeal obstruction can relieve the clinical symptoms more quickly and reduce the total amount of hormone application

without significant adverse drug reactions and without increasing the incidence of nosocomial infection

which is worthy of clinical promotion.